Left Atrial Appendage Closure
21
8
10
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 21 trials
100.0%
+13.4% vs benchmark
14%
3 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (21)
WATCHMAN FLX Pro European Registry
OPTION-EMEA Clinical Trial
Registry on Luma Vision's VERAFEYE System (ENLIgHT)
Agilis RF TSP Early Feasibility Study
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Feasibility Study on the VERAFEYE System
Preventing Neurologic Complications in Valve Surgery
CardioLogical Interventions and Acute strOke Treatment sTudy
Data Collection for Echocardiography-Based Software Assessment
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral
Austrian Left Atrial Appendage Closure Registry
Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure. (SWISS-APERO)
The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial
The Usefulness of Biatrial 3D Printing to Plan Transseptal Puncture for the Left Atrial Appendage Closure
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure
Left Atrial Appendage Closure With the LAmbre
China REgistry of WATCHMAN